Qualigen Therapeutics Files 8-K/A Amendment
Ticker: AIXC · Form: 8-K/A · Filed: Nov 21, 2024 · CIK: 1460702
Sentiment: neutral
Topics: amendment, executive-changes, officer-appointment, financial-statements
TL;DR
Qualigen Therapeutics amended its 8-K filing, updating info on exec changes and compensation.
AI Summary
Qualigen Therapeutics, Inc. filed an amendment (8-K/A) on November 21, 2024, to a previous report dated November 7, 2024. This amendment pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. The filing also includes financial statements and exhibits.
Why It Matters
This amendment provides updated information regarding changes in the company's leadership and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially those concerning executive changes and compensation, can signal internal shifts or challenges within a company.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- November 7, 2024 (date) — Earliest event reported date
- November 21, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Carlsbad, California (location) — Principal executive offices location
FAQ
What specific officer or director departures are detailed in this 8-K/A filing?
The filing indicates it pertains to the 'Departure of Directors or Certain Officers' but does not specify names in the provided text.
What is the primary purpose of this 8-K/A filing?
The primary purpose is to amend a previous report concerning director/officer changes, elections, appointments, and compensation arrangements, as well as to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on November 7, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the SIC code for Qualigen Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Qualigen Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-11-21 17:10:18
Filing Documents
- form8-ka.htm (8-K/A) — 37KB
- ex10-1.htm (EX-10.1) — 193KB
- 0001493152-24-047189.txt ( ) — 434KB
- qlgn-20241107.xsd (EX-101.SCH) — 3KB
- qlgn-20241107_lab.xml (EX-101.LAB) — 33KB
- qlgn-20241107_pre.xml (EX-101.PRE) — 24KB
- form8-ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: November 21, 2024 By: /s/ Kevin Richardson II Kevin Richardson II, Interim Chief Executive Officer